Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension1

Introduction. Aliskiren is the first in a new class of direct renin inhibitors to be approved for the treatment of hypertension. Patients and methods. In this double-blind, multicentre trial, 694 patients with hypertension (mean sitting diastolic blood pressure [BP] ≥ 95 and < 110 mmHg) were randomised to once-daily aliskiren 150 mg (n=231), atenolol 50 mg (n=231) or the combination (150/50 mg; n=232) for six weeks, followed by a further six weeks on double the initial doses of aliskiren and atenolol. Efficacy (reduction from baseline in mean sitting systolic and diastolic BP) and tolerability of study treatments were assessed; plasma renin activity (PRA) was measured in a subset of patients. Results. At Week 12 endpoint, aliskiren, atenolol and aliskiren/atenolol lowered systolic and diastolic BP from baseline by 14.3/11.3, 14.3/13.7 and 17.3/14.1 mmHg, respectively. Systolic BP reductions with aliskiren/atenolol were significantly greater than those with aliskiren (p=0.039) or atenolol (p=0.034) alone, and diastolic BP reductions were greater than with aliskiren alone (p<0.001). Diastolic BP changes were larger with atenolol than with aliskiren (p=0.003, correlating with the large reductions in pulse rate (> 10 bpm) observed with atenolol. Aliskiren, atenolol and aliskiren/atenolol reduced geometric mean PRA from baseline by 65%, 52% and 61%, respectively. In patients with moderate or high baseline PRA (≥ 0.65 ng/ml/hour), PRA was reduced to low levels (< 0.65 ng/ml/hour) at Week 12 endpoint in a greater proportion of patients receiving aliskiren (11/15 patients, 73.3%) or aliskiren/atenolol (18/23, 78.3%) than with atenolol (10/21, 47.6%). Aliskiren treatment was associated with numerically lower rates of adverse events and discontinuations due to adverse events compared with atenolol or combination treatment, and unlike atenolol was not associated with bradycardia. Conclusions. Direct renin inhibition with aliskiren may be an appropriate substitute for beta-blocker treatment in patients with uncomplicated hypertension. Aliskiren also represents an attractive option for dual therapy with atenolol to improve systolic BP/pulse pressure reductions and BP control with maintained tolerability compared with atenolol alone.

[1]  B. Hesse,et al.  Acute and Long-Term Salt Depletion and β-blockade: Plasma Renin Activity Response and its Relation to Blood Pressure Reduction in Long-Term Treatment , 2009 .

[2]  D. Müller,et al.  Aliskiren-Binding Increases the Half Life of Renin and Prorenin in Rat Aortic Vascular Smooth Muscle Cells , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[3]  M. Schalekamp,et al.  Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors , 2008, Journal of hypertension.

[4]  V. Tayal,et al.  Aliskiren: a novel renin inhibitor for hypertension. , 2007, Indian heart journal.

[5]  Y. Uresin,et al.  Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension , 2007, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[6]  G. Caruso,et al.  9.8 A Sanitary Educational Project: “A 10-year More Life Expectancy”: a Bridge on the Mediterranean Area. Preliminary Results , 2007 .

[7]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[8]  Piotr Ponikowski,et al.  2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, European heart journal.

[9]  G. Oster,et al.  Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine , 2007, Journal of Human Hypertension.

[10]  B. Oh,et al.  Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. , 2007, Journal of the American College of Cardiology.

[11]  D. Calhoun,et al.  Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide , 2007, Journal of hypertension.

[12]  D. Sica,et al.  9.9 Aliskiren, a Novel Renin Inhibitor, is Well Tolerated and Has Sustained BP-Lowering Effects Alone or in Combination with HCTZ During Long-Term (52 Weeks) Treatment of Hypertension , 2007 .

[13]  A. Zanchetti,et al.  Erratum: Hypertension: Which aspects of hypertension should we impact on and how? (Journal of Hypertension (2006) 24, SUPPL. 5 (S2-S5)) , 2007 .

[14]  Roland E Schmieder,et al.  Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. , 2007, American journal of hypertension.

[15]  W. Elliott.  Hypertension: Management of hypertension in adults in primary care: partial updateNational Institute for Health and Clinical Excellence ([British] National Collaborating Centre for Chronic Conditions, England; British Hypertension Society, England; Newcastle Guideline Development and Research Unit, , 2007 .

[16]  F. McAlister,et al.  Re-examining the efficacy of β-blockers for the treatment of hypertension: a meta-analysis , 2006, Canadian Medical Association Journal.

[17]  P. Sever.  New Hypertension Guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society , 2006, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[18]  J. Ménard,et al.  Conformational changes in prorenin during renin inhibition in vitro and in vivo , 2006, Journal of hypertension.

[19]  I. Mrdović,et al.  Is the level of evidence for the use of beta-blockers in acute myocardial infarction satisfactory enough? , 2005, European heart journal.

[20]  Alice Stanton,et al.  Differential Impact of Blood Pressure–Lowering Drugs on Central Aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study , 2006, Circulation.

[21]  L. Lindholm,et al.  Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis , 2005, The Lancet.

[22]  B. Williams,et al.  The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension , 2005, Journal of hypertension.

[23]  R. Collins,et al.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.

[24]  C. White,et al.  The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. , 2005, Diabetes care.

[25]  V. Dzau.  The cardiovascular continuum and renin–angiotensin–aldosterone system blockade , 2005, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[26]  Kozo Hirata,et al.  Benefits from angiotensin-converting enzyme inhibitor ‘beyond blood pressure lowering’: beyond blood pressure or beyond the brachial artery? , 2005, Journal of hypertension.

[27]  R. Schmieder,et al.  Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients , 2005, Circulation.

[28]  J F Potter,et al.  Extract from : , 2009 .

[29]  J. Laragh,et al.  Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. , 2004, American journal of hypertension.

[30]  Alice Stanton,et al.  Structure-based design of aliskiren, a novel orally effective renin inhibitor. , 2003, Biochemical and biophysical research communications.

[31]  N J Wald,et al.  Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials , 2003, BMJ : British Medical Journal.

[32]  G. Wuerzner,et al.  Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100): Comparison With Enalapril , 2002, Hypertension.

[33]  T. Lumley,et al.  Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. , 2001, Archives of internal medicine.

[34]  H. Krumholz,et al.  Pulse pressure and risk for myocardial infarction and heart failure in the elderly. , 2000, Journal of the American College of Cardiology.

[35]  Li-sheng Liu,et al.  Pulse Pressure Not Mean Pressure Determines Cardiovascular Risk in Older Hypertensive Patients , 2000 .

[36]  D. Levy,et al.  Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. , 1999, Circulation.

[37]  J. Laragh,et al.  β-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects , 1999 .

[38]  J. Laragh,et al.  Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. , 1999, American journal of hypertension.

[39]  C H Chen,et al.  Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. , 1995, Hypertension.

[40]  Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. Veterans Administration Cooperative Study Group on Antihypertensive Agents. , 1982, JAMA.

[41]  J. Staessen,et al.  Effect of chronic diuretic treatment on the plasma renin-angiotensin-aldosterone system in essential hypertension. , 1981, British journal of clinical pharmacology.

[42]  O. Ohlsson,et al.  Atenolol administered once daily in primary hypertension. Effects on blood pressure in relation to pre-treatment plasma renin activity. , 2009, Acta medica Scandinavica.

[43]  B. Hesse,et al.  Acute and long-term salt depletion and beta-blockade: plasma renin activity response and its relation to blood pressure reduction in long-term treatment. , 1978, Acta medica Scandinavica.

[44]  R. Tarazi,et al.  Dissociation Between Renin and Arterial Pressure Responses to Beta‐Adrenergic Blockade in Human Essential Hypertension , 1975, Circulation research.

[45]  R. Tarazi,et al.  On the mechanism of suppressed plasma-renin activity during beta-adrenergic blockade with propranolol. , 1974, The Journal of laboratory and clinical medicine.

[46]  F. Zacharias.  Beta blockers in hypertension. , 1973, Bruxelles medical.

[47]  J. Laragh,et al.  Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. , 1972, The New England journal of medicine.

[48]  A. Michelakis,et al.  The effect of chronic adrenergic receptor blockade on plasma renin activity in man. , 1972, The Journal of clinical endocrinology and metabolism.